Oncodrivers in Malignant Pleural Effusions Associated With Non-small Cell Lung Cancer: A Prospective Study.

Plain-language summary

This study examines the measurement of oncogenic markers such as PD-L1, ALK, and EGFR in malignant pleural effusions (fluid buildup between the lung membranes) associated with non-small cell lung cancer. It enrolls patients aged 18 and older whose pleural fluid is known or suspected to contain these cancer cells. It is conducted as a study without a phase designation and is currently recruiting participants.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

Not Applicable

Status

Recruiting

Sponsor

Naestved Hospital

Intervention

meassurement of PD-L1, ALK, EGFR

Start date

3/15/2021

Estimated completion

12/31/2028

Countries

Denmark

Related genes

Locations

• Næstved, Denmark

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Age ≥ 18 years
* Pleural effusion known or suspected of association with NSCLC (pleural fluid cytology positive for cells from NSCLC)
* Patients must be able to give informed consent

Exclusion Criteria:

* Full oncodriver status measured in any pleural fluid in current work-up
* Inability to understand written or spoken Danish.